

Peter Lau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7694255/publications.pdf>

Version: 2024-02-01

33
papers

697
citations

687363

13
h-index

580821

25
g-index

36
all docs

36
docs citations

36
times ranked

1277
citing authors

#	ARTICLE	IF	CITATIONS
1	Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses. <i>Frontiers in Immunology</i> , 2018, 9, 70.	4.8	120
2	Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 17990-18000.	7.1	81
3	Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016217454.	0.5	56
4	Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. <i>European Journal of Cancer</i> , 2018, 105, 88-102.	2.8	53
5	FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2776-2786.	6.4	42
6	Artesunate is Ineffective in Controlling Valganciclovir-Resistant Cytomegalovirus Infection. <i>Clinical Infectious Diseases</i> , 2011, 52, 279-279.	5.8	37
7	Activation of Canonical BMP4-SMAD7 Signaling Suppresses Breast Cancer Metastasis. <i>Cancer Research</i> , 2020, 80, 1304-1315.	0.9	37
8	A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies. <i>European Journal of Cancer</i> , 2020, 124, 15-24.	2.8	31
9	Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: A case series. <i>Health Science Reports</i> , 2019, 2, e115.	1.5	29
10	Clinical and palliative care outcomes for patients of poor performance status treated with anti-programmed death-1 monoclonal antibodies for advanced melanoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 385-390.	1.1	27
11	Factors associated with psychological distress amongst outpatient chemotherapy patients: An analysis of depression, anxiety and stress using the DASS-21. <i>Applied Nursing Research</i> , 2018, 40, 45-50.	2.2	25
12	Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition. <i>Current Opinion in Immunology</i> , 2016, 39, 30-38.	5.5	23
13	The evaluation of a clinical scar scale for porcine burn scars. <i>Burns</i> , 2009, 35, 538-546.	1.9	19
14	Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)., 2021, 9, e002995.		18
15	A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy. <i>Scientific Reports</i> , 2019, 9, 1225.	3.3	16
16	Patients Prefer Chemotherapy on the Same Day As Their Medical Oncology Outpatient Appointment. <i>Journal of Oncology Practice</i> , 2014, 10, e380-e384.	2.5	12
17	Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma. <i>Cancer Immunology Research</i> , 2021, 9, 136-146.	3.4	12
18	Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases. <i>European Journal of Cancer</i> , 2021, 156, 149-163.	2.8	11

#	ARTICLE	IF	CITATIONS
19	A pilot study to assess the validity of the DASSâ€21 subscales in an outpatient oncology population. <i>Psycho-Oncology</i> , 2018, 27, 695-699.	2.3	10
20	High-resolution MRI demonstrates that more than 90% of small intracranial melanoma metastases develop in close relationship to the leptomeninges. <i>Neuro-Oncology</i> , 2020, 22, 423-432.	1.2	8
21	Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer. <i>The Cochrane Library</i> , 2021, 2021, CD011220.	2.8	8
22	Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAFV600 melanoma. <i>Nature Communications</i> , 2022, 13, 1100.	12.8	8
23	Marked functional improvement after combined chemoradiotherapy for cervical spine glioblastoma causing quadriplegia in an adolescent. <i>BMJ Case Reports</i> , 2014, 2014, bcr2013202791-bcr2013202791.	0.5	4
24	Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma. <i>Cancers</i> , 2021, 13, 6342.	3.7	4
25	Brain metastases: lessons and challenges in the targeted therapy and immunotherapy era. <i>Journal of Thoracic Disease</i> , 2020, 12, 4527-4530.	1.4	3
26	Capecitabine for ER-positive versus ER-negative breast cancer. <i>The Cochrane Library</i> , 2014, , .	2.8	1
27	Optimal Selection of Targeted Therapies for Melanoma Patients. , 2016, , 169-183.		0
28	1079MO Progression of BRAF mutant CNS metastases are associated with a transcriptional network bearing similarities with the innate PD-1 resistant signature (IPRES). <i>Annals of Oncology</i> , 2020, 31, S733.	1.2	0
29	Abstract P1-01-09: BMP4 suppresses the progression of breast cancer through altered expression of metastasis regulating genes. , 2018, , .		0
30	Checkpoint Inhibitors in the Treatment of Metastatic Melanoma. , 2019, , 1-24.		0
31	FDG-PET metabolic tumor volume in advanced melanoma treated with ipilimumab and nivolumab (ipi/nivo).. <i>Journal of Clinical Oncology</i> , 2020, 38, 10041-10041.	1.6	0
32	INN-08. LOW AND INTERMEDIATE GRADE GLIOMA UMBRELLA STUDY OF MOLECULAR GUIDED THERAPIES (LUMOS) STUDY. <i>Neuro-Oncology</i> , 2021, 23, vi106-vi107.	1.2	0
33	RTID-05. THE MULTI-ARM GLIOBLASTOMA AUSTRALASIA (MAGMA) TRIAL. <i>Neuro-Oncology</i> , 2021, 23, vi193-vi194.	1.2	0